Growing Stock, Growing Generosity
While many individuals choose to support charities through cash donations,
some donors have adopted a new way of giving in the form of stock gifts.
News
Read the Latest Issue of Pulse: Fall 2021
Read the Fall 2021 edition of Pulse. This issue of Pulse pays homage to family caregivers and the critical role they play in a patients' journey.
In Remembrance: Dr. Joseph Bertino
Remembering Joseph R. Bertino, MD, the founding chair of the Lymphoma Research Foundation Scientific Advisory Board.
Three Healthy Ways to Navigate the Internet While Coping with a Lymphoma Diagnosis
Here are some ways lymphoma patients, survivors and caregivers can best navigate the internet for information, emotional and social support needs.
U.S. Food and Drug Administration Approves Ruxolitinib (Jakafi) for Chronic Graft-Versus-Host Disease
Belumosudil (REZUROCK, Kadmon Pharmaceuticals, LLC), is a kinase inhibitor for chronic graft-versus-host disease (chronic GVHD) in adult and pediatric patients 12 years and older.
The U.S. Food and Drug Administration Approves Zanubrutinib for Marginal Zone Lymphoma
On September 14, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
Survivor: Africa Winner, Humanitarian and Cancer Survivor Ethan Zohn Named an Official Ambassador for the Lymphoma Research Foundation
Zohn joins a national LRF Ambassador program in which individuals from around the country share their stories of hope. With more than 100 types of lymphoma, many LRF Ambassadors’ diagnoses are different.
Ask the Doctor: What is the difference between primary cutaneous, systemic, and breast-implant associated ALCL?
Milos Miljkovic, MD MSc of the National Cancer Institute Center for Cancer Research discusses the main differences between these types of ALCL, how they are diagnosed, and typical frontline therapies.
The U.S. Food and Drug Administration Approves Zanubrutinib for Waldenstrӧm Macroglobulinemia
On August 31, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with Waldenstrӧm macroglobulinemia (WM).
Ask the Doctor: What is minimal residual disease (MRD)?
Krish Patel, MD of the Swedish Cancer Institute discusses how MRD is measured and what patients should know about testing for it.
Stay informed with news, alerts and other resources.
